Nicotinic Receptors Containing the Alpha7 Subunit: a Model for Rational Drug Design

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2008 Dec 17

PMID 19075644

Citations 10

Authors

G Sharma

S Vijayaraghavan

Affiliations

Soon will be listed here.

Abstract

The neuronal nicotinic receptor has gained considerable recognition as a target, not just for combating drug addiction but also for treating a number of illnesses ranging from neurodegenerative diseases to psychotic disorders like schizophrenia. This recognition has led to a burgeoning field examining the receptor at all levels. A class of nicotinic receptors that contains the alpha7 gene product, apparently as a homomer, illustrates this multidisciplinary approach. Here, we review recent progress in our understanding of this class of receptors based on data from molecular, structural, physiological and patho-physiological studies. These studies have set the stage for rational drug design to combat disorders of the central nervous system. The studies also exemplify the cautious approach needed in developing CNS therapies and the importance of physiology in tempering drug design.

Citing Articles

Nicotine Motivated Behavior in .

Salim C, Batsaikhan E, Kan A, Chen H, Jee C Int J Mol Sci. 2024; 25(3).

PMID: 38338915 PMC: 10855306. DOI: 10.3390/ijms25031634.

nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.

Parikh V, Kutlu M, Gould T Schizophr Res. 2016; 171(1-3):1-15.

PMID: 26803692 PMC: 4762752. DOI: 10.1016/j.schres.2016.01.020.

Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration.

Mello N, Fivel P, Kohut S, Carroll F Neuropsychopharmacology. 2013; 39(5):1222-31.

PMID: 24304823 PMC: 3957118. DOI: 10.1038/npp.2013.325.

Cell-free Production of the Extracellular Domain of the Nicotinic Acetylcholine Receptor.

Lyukmanova E, Kopeina G, Shulepko M, Shenkarev Z, Arseniev A, Dolgikh D Acta Naturae. 2012; 1(1):96-8.

PMID: 22649592 PMC: 3347502.

Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Finlay-Schultz J, Canastar A, Short M, El Gazzar M, Coughlan C, Leonard S J Biol Chem. 2011; 286(49):42123-42132.

PMID: 21979958 PMC: 3234925. DOI: 10.1074/jbc.M111.276014.

References

Cammarota M, Bevilaqua L, Viola H, Kerr D, Reichmann B, Teixeira V . Participation of CaMKII in neuronal plasticity and memory formation. Cell Mol Neurobiol. 2002; 22(3):259-67. PMC: 11533765. DOI: 10.1023/a:1020763716886. View

Uteshev V, Meyer E, Papke R . Activation and inhibition of native neuronal alpha-bungarotoxin-sensitive nicotinic ACh receptors. Brain Res. 2002; 948(1-2):33-46. DOI: 10.1016/s0006-8993(02)02946-3. View

Berke J, Hyman S . Addiction, dopamine, and the molecular mechanisms of memory. Neuron. 2000; 25(3):515-32. DOI: 10.1016/s0896-6273(00)81056-9. View

Szabo S, Zelles T, Lendvai B . Intracellular Ca2+ dynamics of hippocampal interneurons following nicotinic acetylcholine receptor activation. Neurochem Int. 2007; 52(1-2):135-41. DOI: 10.1016/j.neuint.2007.05.012. View

Hunter B, De Fiebre C, Papke R, Kem W, Meyer E . A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci Lett. 1994; 168(1-2):130-4. DOI: 10.1016/0304-3940(94)90433-2. View

Benowitz N, Henningfield J . Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N Engl J Med. 1994; 331(2):123-5. DOI: 10.1056/NEJM199407143310212. View

Thiagarajan T, Piedras-Renteria E, Tsien R . alpha- and betaCaMKII. Inverse regulation by neuronal activity and opposing effects on synaptic strength. Neuron. 2002; 36(6):1103-14. DOI: 10.1016/s0896-6273(02)01049-8. View

Mansvelder H, de Rover M, McGehee D, Brussaard A . Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur J Pharmacol. 2003; 480(1-3):117-23. DOI: 10.1016/j.ejphar.2003.08.099. View

Nakayama H, Fujihara S, Nakashima T, Kurogochi Y . Formation of two major nicotine metabolites in livers of guinea pigs. Biochem Pharmacol. 1987; 36(24):4313-7. DOI: 10.1016/0006-2952(87)90677-0. View

10.

Pugh P, Margiotta J . Nicotinic acetylcholine receptor agonists promote survival and reduce apoptosis of chick ciliary ganglion neurons. Mol Cell Neurosci. 2000; 15(2):113-22. DOI: 10.1006/mcne.1999.0810. View

11.

Messina E, Tyndale R, Sellers E . A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther. 1997; 282(3):1608-14. View

12.

Yamano S, Tatsuno J, Gonzalez F . The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry. 1990; 29(5):1322-9. DOI: 10.1021/bi00457a031. View

13.

Henchman R, Wang H, Sine S, Taylor P, McCammon J . Asymmetric structural motions of the homomeric alpha7 nicotinic receptor ligand binding domain revealed by molecular dynamics simulation. Biophys J. 2003; 85(5):3007-18. PMC: 1303578. DOI: 10.1016/S0006-3495(03)74720-1. View

14.

Papke R, Meyer E, Nutter T, Uteshev V . alpha7 receptor-selective agonists and modes of alpha7 receptor activation. Eur J Pharmacol. 2000; 393(1-3):179-95. DOI: 10.1016/s0014-2999(00)00009-1. View

15.

Luck W, Nau H, Hansen R, Steldinger R . Extent of nicotine and cotinine transfer to the human fetus, placenta and amniotic fluid of smoking mothers. Dev Pharmacol Ther. 1985; 8(6):384-95. DOI: 10.1159/000457063. View

16.

Sharma G, Vijayaraghavan S . Nicotinic receptor signaling in nonexcitable cells. J Neurobiol. 2002; 53(4):524-34. DOI: 10.1002/neu.10114. View

17.

Jellinger K . Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl. 2002; (62):347-76. DOI: 10.1007/978-3-7091-6139-5_33. View

18.

Marshall D, Redfern P, Wonnacott S . Presynaptic nicotinic modulation of dopamine release in the three ascending pathways studied by in vivo microdialysis: comparison of naive and chronic nicotine-treated rats. J Neurochem. 1997; 68(4):1511-9. DOI: 10.1046/j.1471-4159.1997.68041511.x. View

19.

Astles P, Baker S, Boot J, Broad L, Dell C, Keenan M . Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord. 2003; 1(4):337-48. DOI: 10.2174/1568007023339256. View

20.

Luu P, Malenka R . Spike timing-dependent long-term potentiation in ventral tegmental area dopamine cells requires PKC. J Neurophysiol. 2008; 100(1):533-8. PMC: 2493500. DOI: 10.1152/jn.01384.2007. View